Popularized in films like Limitless, legal smart drugs called Nootropics are becoming more and more prevalent in board rooms and on Wall Street.Keep reading »
The hedge fund, one of Europe’s largest, saw its fee income fall by nearly two-thirds in the year ended March 2013, according to a regulatory filing. And that means that its 46 members had to settle for splitting £60.4 million, down from £269.8 million in the previous fiscal year.
The highest-paid partner at the US$40 billion firm, presumably founder Alan Howard, received £39.4 million, about half of the £78.9 million he earned in the prior 12 months. The average payout fell to £1.31 million from £5.51 million in the year ended March 2012.
Brevan Partners Split Shrunken Profit Pool [FINalternatives]